Skip to main content
Jonathan Villena-Vargas, MD, Thoracic Surgery, New York, NY

JonathanVillena-VargasMD

Thoracic Surgery • New York, NY

Cardiovascular Surgery

Physician

Request Appointment

Overview of Dr. Villena-Vargas

Dr. Jonathan Villena-Vargas is a thoracic surgeon in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, New York-Presbyterian Hospital, NewYork-Presbyterian Brooklyn Methodist Hospital, New York-Presbyterian Queens, NewYork-Presbyterian/Columbia University Irving Medical Center, Mount Sinai Beth Israel, and Memorial Sloan Kettering Cancer Center. He received his medical degree from Loma Linda University School of Medicine and has been in practice 8 years. He is one of 30 doctors at Mount Sinai Beth Israel and one of 143 doctors at New York-Presbyterian Hospital who specialize in Thoracic Surgery. He also speaks multiple languages, including Spanish and Portuguese. He has more than 30 publications and over 500 citings.

Education & Training

  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Fellowship, Thoracic Surgery, 2017 - 2019
  • Icahn School of Medicine at Mount Sinai (Beth Israel)
    Icahn School of Medicine at Mount Sinai (Beth Israel)Residency, Surgery, 2009 - 2017
  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Immunology/Oncology Research Fellowship, 2011 - 2014
  • Loma Linda University School of Medicine
    Loma Linda University School of MedicineClass of 2009

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2019 - 2026
  • American Board of Thoracic Surgery Thoracic and Cardiac Surgery

Publications & Presentations

PubMed

Press Mentions

  • Late-Stage Cancer Diagnoses Rise After Pandemic-Related Drop in Screenings
    Late-Stage Cancer Diagnoses Rise After Pandemic-Related Drop in ScreeningsJuly 25th, 2022
  • Surgical Resection After Neoadjuvant Durvalumab and Radiation Is Feasible and Safe in Non-Small Cell Lung Cancer: Results from a Randomized Trial
    Surgical Resection After Neoadjuvant Durvalumab and Radiation Is Feasible and Safe in Non-Small Cell Lung Cancer: Results from a Randomized TrialMay 17th, 2022

Other Languages

  • Spanish, Portuguese

Dr. Jonathan Villena-Vargas, Dr. Jonathan Villena-Vargas, MD, Dr. J Villena-Vargas